Skip to main content
SpringerLink
Log in

Thrombolytic therapy in acute myocardial infarction—Selected recent developments

  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Thrombolytic therapy is the established treatment of choice for most eligible patients with acute myocardial infarction. Early initiation of treatment and early, complete and maintained patency of the infarctrelated coronary artery are desirable, because these variables correlate with a reduction in mortality. As a consequence, considerable efforts have been undertaken to develop new pharmacological agents that serve these purposes. Among these, new plasminogen activators such as reteplase (r-PA), saruplase (scuPA), and staphylokinase are in clinical development, and DSPA (bat t-PA) and antibody-targeted plasminogen activators (ScuPA-59D8) have undergone extensive animal testing. Anticoagulants such as recombinant hirudin, hirulog, argatrobane, and Factor Xa inhibitors, as well as antiplatelet agents on the basis of monoclonal antibody 7E3 offer promise as adjunctive therapy to thrombolysis or to invasive intracoronary procedures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. AIMS Trial Study Group (1988) Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1:545–549

    Google Scholar 

  2. AIMS Trial Study Group (1990) Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet 335:427–431

    Google Scholar 

  3. Bleich SD, Nichols T, Schumacher R, Cooke D, Tate D, Steiner C, Brinkman D (1990) The role of heparin following coronary thrombolysis with tissue plasminogen activator (t-PA). Am J Cardiol 66:1412–1417

    PubMed  Google Scholar 

  4. Bode C, Baumann H, von Hodenberg E, Freitag M, Nordt T (1993) Combinations of thrombolytic agents in acute myocardial infarction. Z Kardiol 82 [Suppl 2]:125–128

    PubMed  Google Scholar 

  5. Bode C, Hudelmayer M, Mehwald P, Bauer S, Freitag M, von Hodenberg E, Newell JB, Kübler W, Haber E, Runge MS (1994) Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than untargeted hirudin. Circulation (in press)

  6. Bode C, Meinhardt G, Runge MS, Nordt T, Freitag M, Arens M, Kübler W, Haber E (1991) Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation 84:805–813

    PubMed  Google Scholar 

  7. Bode C, Matsueda GR, Hui KY, Haber E (1985) Antibody-directed urokinase: a specific fibrinolytic agent. Science 229:765–767

    PubMed  Google Scholar 

  8. Bode C, Peter K, Kübler W, Katus HA (1994) Aggressive thrombolytische Therapie des Myokardinfarktes — Grenzen und Möglichkeiten. Z Kardiol 83:393–403

    PubMed  Google Scholar 

  9. Bode C, Runge MS, Newell JB, Matsueda GR, Haber E (1987) Characterization of an antibody-urokinase conjugate: a plasminogen activator targeted to fibrin. J Biol Chem 262:10819–10823

    PubMed  Google Scholar 

  10. Bode C, Runge MS, Schönermark S, Eberle T, Newell JB, Kübler W, Haber E (1990) Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 81:1974–1980

    PubMed  Google Scholar 

  11. Bode C, Schönermark S, Schuler G, Zimmermann R, Schwarz F, Kübler W (1988) Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction. Am J Cardiol 61:971–974

    PubMed  Google Scholar 

  12. Bode C, Schuler G, Nordt T, Schönermark S, Baumann H, Richardt G, Dietz R, Gurewich V, Kübler W (1990) Intravenous thrombolytic therapy with a combination of single-chain urokinasetype plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. Circulation 81:907–913

    PubMed  Google Scholar 

  13. Bode C, Smalling RW, Sen S, Kalbfleisch J, Boehm E, Odenheimer DJ, Meyer Sabellek W, and the RAPID Investigators (1993) Recombinant plasminogen activator angiographic phase-II international dose-finding study (RAPID): patency analysis and mortality endpoints. Circulation 88:[Suppl]I-292

    Google Scholar 

  14. Cannon CP, McCabe CH, Henry TD, Schweiger M, Gibson RS, Mueller H, Becker R, Kleiman NS, Braunwald E for the TIMI 5 investigators (1994) A pilot trial of recombinant de-sulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993–1003

    PubMed  Google Scholar 

  15. Collen D, van de Werf F (1993) Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 87:1850–1853

    PubMed  Google Scholar 

  16. DeBono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Lopez-Bescos L, Mueller E, Pfisterer J, Van de Werf F, Zijlstra F, Verstraete M, for the European cooperative Study Group (1992) Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized, double blind European Cooperative Study Group Trial. Br Heart J 67:122–128

    PubMed  Google Scholar 

  17. Dichek DA (1993) Gene transfer in the treatment of thrombosis. Thromb Haemost 70:198–201

    PubMed  Google Scholar 

  18. EMIP Group (1993) Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction N Engl J Med 329:383–389

    Google Scholar 

  19. Fibrinolytic Therapy Trialists (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 343:311–322

    Google Scholar 

  20. Gardell SJ, Ramjit DR, Stabilito JJ, Tsuneo F, Lynch JJ, Guca GC, Deepak F, Wang S, Tung J, Mark GE, Shubuski RJ (1991) Effective thrombolysis without marked plasminemia following bolus intravenous administration of a vampire bat salivary plasminogen activator in rabbits. Circulation 84:244–253

    PubMed  Google Scholar 

  21. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ, for the Mayo Coronary Care Unit and Catheterization Groups (1993) Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 328:685–691

    PubMed  Google Scholar 

  22. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Hot R, Jordan R, Berger H, Collen D, Coller BS (1990) Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 86:651–659

    PubMed  Google Scholar 

  23. GREAT Group (1992) Feasability, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. Br Med J 305:548–553

    Google Scholar 

  24. Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Puchrowicz-Ochocki S, O'Neill WW for the primary angioplasty in myocardial infarction study group (1993) A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 328:673–679

    PubMed  Google Scholar 

  25. Gruppo Italiano per Io Studio della Sopravivenza nell'Infarto Miocardico (1990) GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 336:65–71

    Google Scholar 

  26. Gruppo Italiano per Io studio della streptochinasi nell' infarto miocardico (GISSI) (1986) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1:397–402

    Google Scholar 

  27. Gruppo Italiano per Io studio della streptochinasi nell' infarto miocardico (GISSI) (1987) Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 2:871–874

    Google Scholar 

  28. Gulba DC, MJ Gallimore, L Creighton, R Frombach, S Jost, PR Lichtlen (1990) Während der Infarktlyse mit präaktivierter Pro-urokinase ist eine hohe systemische Urokinaseaktivität messbar. Z Kardiol 79: [Suppl 1] Abstract 166

    PubMed  Google Scholar 

  29. GUSTO Angiographic Investigators (1993) The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329:1615–1622

    Google Scholar 

  30. GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682

    Google Scholar 

  31. Haskel EJ, Prager NA, Sobel BE, Abendschein DR (1991) Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 83:1048–1056

    PubMed  Google Scholar 

  32. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM for the HART Investigators (1990) A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 323:1433–1437

    PubMed  Google Scholar 

  33. ISIS-2 Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17189 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2:349–360

    Google Scholar 

  34. ISIS-3 Collaborative Group (1992) ISIS-3:a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs heparin alone among 41299 cases of suspected acute myocardial infarction. Lancet 339:753–770

    Google Scholar 

  35. Neuhaus KL, Niederer W, Wagner J, Mäurer W, von Essen R, Tebbe U, von Leitner ER, Haerten K, Vogt A, Appel KF, Mateblowsli M, Zeymer U for the ALKK study group (1993) HIT (hirudin for the improvement of thrombolysis): results of a dose escalation study. Circulation 88: [Suppl] I-292

    Google Scholar 

  36. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereiakes D, George B, Stack R, and the TAMI study group (1990) Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 82:781–791

    PubMed  Google Scholar 

  37. Popma JJ, Topol EJ (1991) Adjuncts to thrombolysis for myocardial reperfusion. Ann Intern Med 115:34–44

    PubMed  Google Scholar 

  38. Prins MH, Hirsh J (1991) Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 67:2A-11A

    Google Scholar 

  39. Ribeiro EE, Silva LA, Carneiro R, D'Oliveira LG, Gasquez A, Amino JG, Tavares JR, Petrizzo A, Torossian S, Duprat R, Buffalo E, Ellis SG (1993) Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 22:376–380

    PubMed  Google Scholar 

  40. Runge MS, Bode C, Matsueda GR, Haber E (1988) Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Biochemistry 27:1153–1157

    PubMed  Google Scholar 

  41. Runge MS, Bode C, Matsueda GR, Haber E (1987) Antibo dy-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci USA 84:7659–7662

    PubMed  Google Scholar 

  42. Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Caban R, Shaw SY, Haber E, Hanson SR (1995) Increased thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons, (in press)

  43. Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw SY, Huang PL, Chou CC, Mullins D, Schnee JM, Savard CE, Rothenberg ME, Newell JB, Matsueda GR, Haber E (1991) A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci USA 88:10337–10341

    PubMed  Google Scholar 

  44. Rustige J, Burczyk U, Werner A, Senges J (1990) Akuter Herzinfarkt. Verkürzung der Prähospitalphase durch Massenaufklärung möglich. Dtsch Arztebl 18:1450–1454

    Google Scholar 

  45. The EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956–961

    Google Scholar 

  46. Theroux P, Kleiman N, Shah P, Williams M, Gill J, Rodriguez S, Niederman A, Broderick JT, Josephson R, Deschenes N, Fitzpatrick V, Sax FL for the MK-852 Investigators (1993) A double-blind, heparin-controlled study of MK-852 in unstable angina. Circulation 88: [Suppl] 1–201

    Google Scholar 

  47. The TIMI Study Group (1985) The thrombolysis in myocardial infarction (TIMI) trial. Phase-I results. N Engl J Med 312:932–936

    Google Scholar 

  48. The PRIMI Study Group (1989) Randomized double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1:863–867

    Google Scholar 

  49. Thompson PL, Aylward PE, Federman J, Giles RW, Harris PJ, Hodge RL, Nelson A, Thomson A, Tonkin AM, Walsh WF (1991) A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. Circulation 85:1534–1542

    Google Scholar 

  50. Topol EJ, George BS, Kereiakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM and the TAMI Study Group (1989) A randomized controlled trial of intravenous tissue-type plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79:281–286

    PubMed  Google Scholar 

  51. Verstraete M, Bernard R, Bory M (1985) Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for recombinant tissue-type plasminogen activator. Lancet 1:842–847

    PubMed  Google Scholar 

  52. Weaver DW, Cerqueira M, Haistrom AP (1994) The myocardial infarction triage and intervention trial of pre-hospital vs hospital initiated thrombolytic therapy. JAMA (in press)

  53. White HD, Charbonnier B, Van de Werf F, Erhardt L, David D, Hillis W, von der Lippe G, Verheugt F, Jennings G, Braun D, Fitzpatrick V, Sax FL (1993) An aspirin-controlled study of MK-852 in patients with unstable angina. Circulation 88: [Suppl] 1–201

    Google Scholar 

  54. Wilcox RG, von der Lippe G, Olsson CG, Jenssen G, Skene AM, Hampton JR (1988) Trial of tissue plasminogen activator (rt-PA) for mortality reduction in acute myocardial infarction: the Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 2:525–530

    PubMed  Google Scholar 

  55. Yusuf S, Sleight P, Held P, MacMahon S (1990) Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. Circulation 82:[Suppl]II 117–134

    Google Scholar 

  56. Zijlstra F, De Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H (1993) A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 328:680–684

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Universität Heidelberg, Bergheimerstrasse 58, D-69115, Heidelberg, Germany

    C. Bode & T. K. Nordt

  2. Division of Cardiology and Sealy Center for Molecular Cardiology, University of Texas Medical Branch at Galveston, 301 University Boulevard, 77555-0553, Gaveston, TX, USA

    M. S. Runge

Authors
  1. C. Bode
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. K. Nordt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. S. Runge
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bode, C., Nordt, T.K. & Runge, M.S. Thrombolytic therapy in acute myocardial infarction—Selected recent developments. Ann Hematol 69, S35–S40 (1994). https://doi.org/10.1007/BF02215957

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02215957

Keywords

Search

Navigation